Biomedical companies face unique challenges when it comes to media communication. Crisis communication, in particular, can make or break a company — all the more so in a sector as sensitive as healthcare.
Crises can strike a biotech company at any point — the dream partner company that had shot you to fame dumps you just before your treatment candidate goes into trial, sending your shares through the floor; or a freak adverse effect pops up during a phase III trial and suddenly all the media are at your door, asking questions that you are only just starting to explore. How can a company survive such a crisis and turn it into an opportunity?
The healthcare sector overall is thriving financially amid the Covid-19 pandemic and the economic fallout of widespread lockdowns that has rocked economies around the world. This is in part because healthcare is seen by investors as an essential service and a relatively safe investment. Down the road, that means more research, more clinical trials,
